Related Experiment Videos
A competitive nucleic acid sequence-based amplification assay for the quantification of human MDR1 transcript in
Tsukasa Hayashi1, Hiroyuki Kobayashi, Hayato Miyachi
1KAINOS Laboratories Inc., 2-38-18 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Summary
A new quantitative nucleic acid sequence-based amplification (NASBA) assay accurately detects multidrug resistance-1 (MDR1) gene expression in clinical samples, aiding in the identification of drug resistance.
Area of Science:
- Molecular Biology
- Biochemistry
- Clinical Diagnostics
Background:
- Clinical drug resistance is often linked to low-level gene expression, necessitating sensitive detection methods.
- The multidrug resistance-1 (MDR1) gene is a key factor in clinical drug resistance.
- Developing precise assays for MDR1 transcript detection is crucial for patient treatment.
Purpose of the Study:
- To develop and validate a quantitative nucleic acid sequence-based amplification (NASBA) assay for MDR1 transcripts.
- To assess the assay's sensitivity, dynamic range, and applicability to clinical samples.
Main Methods:
- Quantitative nucleic acid sequence-based amplification (NASBA) technique was employed.
- Sandwich hybridization and chemiluminescence detection were utilized for amplified MDR1 mRNA.
- Competitive coamplification with in vitro-generated RNA served as an internal control for quantification.
Main Results:
- The developed NASBA assay demonstrated superior sensitivity (100 copies MDR1 mRNA) and a wider dynamic range compared to RT-PCR.
- The assay successfully quantified MDR1 transcripts in 33 clinical leukemia samples.
- MDR1 expression levels in patient samples varied, with some exceeding healthy adult medians.
Conclusions:
- The quantitative NASBA assay is effective for MDR1 mRNA quantification in clinical settings.
- This assay can contribute to the early detection and management of clinical multidrug resistance.